Efficacy of a seal-wing paclitaxel-eluting balloon catheters in
the treatment of bare metal stent restenosis

J 2017

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

PLEVA, L., P. KUKLA, J. ZAPLETALOVA and Ota HLINOMAZ

Basic information

Original name

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

Authors

PLEVA, L. (203 Czech Republic), P. KUKLA (203 Czech Republic), J. ZAPLETALOVA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, guarantor, belonging to the institution)

Edition

BMC Cardiovascular Disorders, London, Biomed Central Ltd, 2017, 1471-2261

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.812

RIV identification code

RIV/00216224:14110/17:00099995

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12872-017-0602-6

UT WoS

000404166900001

Keywords in English

In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent

Abstract

V originále

Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.

Citovat

PLEVA, L., P. KUKLA, J. ZAPLETALOVA and Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. BMC Cardiovascular Disorders. London: Biomed Central Ltd, 2017, vol. 17, No 6, p. 1-9. ISSN 1471-2261. Available from: https://dx.doi.org/10.1186/s12872-017-0602-6.

@article{1408003,
   author = {Pleva, L. and Kukla, P. and Zapletalova, J. and Hlinomaz, Ota},
   article_location = {London},
   article_number = {6},
   doi = {http://dx.doi.org/10.1186/s12872-017-0602-6},
   keywords = {In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent},
   language = {eng},
   issn = {1471-2261},
   journal = {BMC Cardiovascular Disorders},
   title = {Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis},
   volume = {17},
   year = {2017}
}

TY  - JOUR
ID  - 1408003
AU  - Pleva, L. - Kukla, P. - Zapletalova, J. - Hlinomaz, Ota
PY  - 2017
TI  - Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
JF  - BMC Cardiovascular Disorders
VL  - 17
IS  - 6
SP  - 1-9
EP  - 1-9
PB  - Biomed Central Ltd
SN  - 14712261
KW  - In-stent restenosis
KW  - Paclitaxel-elution balloon
KW  - Drug-eluting stent
N2  - Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.
ER  -

PLEVA, L., P. KUKLA, J. ZAPLETALOVA and Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. \textit{BMC Cardiovascular Disorders}. London: Biomed Central Ltd, 2017, vol.~17, No~6, p.~1-9. ISSN~1471-2261. Available from: https://dx.doi.org/10.1186/s12872-017-0602-6.

Detailed Information on Publication Record